Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. More Details
Adequate balance sheet and slightly overvalued.
Share Price & News
How has Hologic's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: HOLX is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: HOLX's weekly volatility (5%) has been stable over the past year.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: HOLX exceeded the US Medical Equipment industry which returned 16.3% over the past year.
Return vs Market: HOLX exceeded the US Market which returned 19.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Hologic's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StNews Flash: Analysts Just Made A Sizeable Upgrade To Their Hologic, Inc. (NASDAQ:HOLX) Forecasts
3 weeks ago | Simply Wall StHologic, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
3 weeks ago | Simply Wall StIs Hologic, Inc.'s (NASDAQ:HOLX) 22% ROE Better Than Average?
Is Hologic undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: HOLX ($69.51) is trading above our estimate of fair value ($45.54)
Significantly Below Fair Value: HOLX is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: HOLX is good value based on its PE Ratio (16.4x) compared to the US Medical Equipment industry average (48.6x).
PE vs Market: HOLX is good value based on its PE Ratio (16.4x) compared to the US market (19.7x).
Price to Earnings Growth Ratio
PEG Ratio: HOLX's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: HOLX is overvalued based on its PB Ratio (6.6x) compared to the US Medical Equipment industry average (4.4x).
How is Hologic forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HOLX's earnings are forecast to decline over the next 3 years (-15.2% per year).
Earnings vs Market: HOLX's earnings are forecast to decline over the next 3 years (-15.2% per year).
High Growth Earnings: HOLX's earnings are forecast to decline over the next 3 years.
Revenue vs Market: HOLX's revenue is expected to decline over the next 3 years (-1.5% per year).
High Growth Revenue: HOLX's revenue is forecast to decline over the next 3 years (-1.5% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HOLX's Return on Equity is forecast to be low in 3 years time (14.1%).
How has Hologic performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HOLX has high quality earnings.
Growing Profit Margin: HOLX became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: HOLX's earnings have declined by 1.8% per year over the past 5 years.
Accelerating Growth: HOLX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: HOLX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (0.2%).
Return on Equity
High ROE: Whilst HOLX's Return on Equity (41.02%) is outstanding, this metric is skewed due to their high level of debt.
How is Hologic's financial position?
Financial Position Analysis
Short Term Liabilities: HOLX's short term assets ($2.2B) exceed its short term liabilities ($1.2B).
Long Term Liabilities: HOLX's short term assets ($2.2B) do not cover its long term liabilities ($3.2B).
Debt to Equity History and Analysis
Debt Level: HOLX's debt to equity ratio (113.1%) is considered high.
Reducing Debt: HOLX's debt to equity ratio has reduced from 173.6% to 113.1% over the past 5 years.
Debt Coverage: HOLX's debt is well covered by operating cash flow (29.3%).
Interest Coverage: HOLX's interest payments on its debt are well covered by EBIT (10.3x coverage).
What is Hologic current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate HOLX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HOLX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HOLX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HOLX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HOLX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Steve MacMillan (56 yo)
Mr. Stephen P. MacMillan, also known as Steve, has been the Chairman of the Board at Hologic Inc. since June 17, 2015 and its Chief Executive Officer and President since December 9, 2013. Mr. MacMillan ser...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD12.37M) is about average for companies of similar size in the US market ($USD10.83M).
Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.
|Chief Financial Officer||2.25yrs||US$2.46m||0.022% |
|General Counsel||5.75yrs||US$2.62m||0.052% |
|Division President of Diagnostic Solutions||3.25yrs||US$2.74m||0.015% |
|Senior Advisor to Chief Executive Officer||0.17yr||US$2.59m||0.0087% |
|Vice President of Investor Relations & Corporate Communications||no data||no data||no data|
|Senior Vice President of Human Resources||5.75yrs||no data||0.018% |
|Group President of International||no data||no data||0.018% |
|Regional President of Asia Pacific||no data||no data||no data|
|Chief of Staff||1.83yrs||no data||no data|
|Chief Supply Chain Officer and Corporate VP of Quality Assurance & Regulatory Affairs||2.83yrs||no data||no data|
Experienced Management: HOLX's management team is considered experienced (3.3 years average tenure).
|Independent Director||7.5yrs||US$298.98k||0.022% |
|Lead Independent Director||3.83yrs||US$321.98k||0.048% |
|Independent Director||2yrs||US$314.74k||0.0011% |
|Independent Director||3.5yrs||US$299.36k||0.0077% |
|Independent Director||9yrs||US$279.98k||0.014% |
|Independent Director||2.83yrs||US$281.48k||0.0045% |
|Independent Director||3.92yrs||US$279.98k||0.0040% |
Experienced Board: HOLX's board of directors are considered experienced (3.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Hologic, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Hologic, Inc.
- Ticker: HOLX
- Exchange: NasdaqGS
- Founded: 1985
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$17.536b
- Shares outstanding: 257.01m
- Website: https://www.hologic.com
Number of Employees
- Hologic, Inc.
- 250 Campus Drive
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|HOLX||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Mar 1990|
|HO1||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Mar 1990|
|HOLX||WBAG (Wiener Boerse AG)||Yes||Common Stock||AT||EUR||Mar 1990|
|0J5Q||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Mar 1990|
|HO1||ETLX (Eurotlx)||Yes||Common Stock||IT||EUR||Mar 1990|
|HOLX *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Mar 1990|
|H1OL34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR EACH 1 REPR 1 SHS UNSPON||BR||BRL||Jan 2020|
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/11/27 23:34|
|End of Day Share Price||2020/11/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.